The delivery of stimulatory signals to dendritic cells (DCs) in the tumor microenvironment could be an effective means to break tumorinduced tolerance. The work presented here evaluates the immunostimulatory properties of pathogen-associated molecular patterns (PAMPs), microbial molecules which bind Toll-like receptors and deliver activating signals to immune cells, when expressed in tumor cells using adenoviral (Ad) vectors. In vitro, transduction of A549 tumor cells with Ad vectors expressing either flagellin from Listeria monocytogenes or P40 protein from Klebsiella pneumoniae induced the maturation of human monocyte-derived DCs in co-cultures. In mixed lymphocyte reactions (MLRs), Ad-flagellin and Ad-P40 transduction of tumor cells stimulated lymphocyte proliferation and the secretion of IFN-g. In vivo, these vectors were used either as stand-alone immunoadjuvants injected intratumorally or as vaccine adjuvants combined with a tumor antigen-expressing vector. When Ad-PAMPs were administered intratumorally to mice bearing subcutaneous syngeneic B16F0-CAR (cocksackie-adenovirus receptor) melanomas, tumor progression was transiently inhibited by Ad-P40. In a therapeutic vaccine setting, the combination of Ad-MUC1 and Ad-PAMP vectors injected subcutaneously delayed the growth of implanted RenCa-MUC1 tumors and improved tumor rejection when compared with vaccination with Ad-MUC1 alone. These results suggest that Ad-PAMPs could be effective immunoadjuvants for cancer immunotherapy.
Introduction
One mechanism by which tumors induce immunosuppression is the functional inhibition of antigen-presenting cells, resulting in inefficient stimulation of the cytotoxic T-cell responses required for tumor cell lysis. Dendritic cells (DCs) are professional antigen-presenting cells that play an important role in immune resistance to tumors. 1 Cancer patients present defects in the myeloid cell compartment with an accumulation of immature myeloid cells and reduced numbers of differentiated DCs. 2 Moreover, in cancer patients as in tumor-bearing mice, DCs are found in an immature state characterized by low expression of costimulatory molecules and weak antigen presentation capacity. [2] [3] [4] This impaired DC function may be a local or a systemic phenomenon. 2 Although immature myeloid cells or DCs induce T-cell unresponsiveness and tolerance notably through the development of regulatory T cells, activated or mature DCs can stimulate lymphocyte proliferation and Th1-oriented antitumor responses. [1] [2] [3] [4] [5] [6] [7] [8] Current knowledge suggests that successful immunotherapy of cancer should involve breaking of tumorinduced tolerance. This requires powerful adjuvants to adjunct cancer vaccines. The delivery of stimulatory signals to DCs directly in the tumor microenvironment could be an effective means to stimulate a tumor-specific immune response. Indeed, many reports have documented the presence of DCs in human tumors, including melanoma, breast, lung, head and neck, and prostate cancers. 2 Harnessing this population offers some advantages as all potential tumor antigens are available at this site and if proper activation of the tumor-infiltrating DCs is provided, they have the potential to stimulate T cells and tumor rejection. 9, 10 With this in mind, intratumoral administration of ligands for Toll-like receptors (TLRs) is being explored as a means to deliver activating signals to immune cells 9, [11] [12] [13] and has been shown to act favorably for the host in the context of cancer immunotherapy. 14, 15 The evolutionary conserved family of TLR mediates signals regulating innate and adaptive immunity. 16 At least 11 different TLRs in human or mouse have been identified with varying expression patterns on DCs, macrophages, other APCs and lymphocytes.
Microbial products termed pathogen-associated molecular patterns (PAMPs), which may be proteins, lipids and/or glycans, activate TLRs thereby triggering innate immunity. The binding of PAMPS to TLRs induces the expression of co-stimulatory molecules on DCs and the production of cytokines, which may drive Th1-or Th2-type responses.
14 When expressed on the surface of tumor cells, PAMPs may be recognized as 'danger signals' by tumor-resident DCs and other TLR-expressing cells 17 and trigger a potent immune response.
The stimulatory properties of the P40 protein from Klebsiella pneumoniae (outer membrane protein A, KpOmpA) have been demonstrated on human and murine antigen-presenting cells. 18, 19 P40 binds TLR2 on the surface of antigen-presenting cells (DCs and macrophages) and induces the phenotypic maturation of DCs, [18] [19] [20] secretion of interleukin (IL)-12 and the inflammatory cytokines IL-6, IL-8 and tumor necrosis factor (TNF)-a. P40 mixed with a tumor antigen peptide was shown to elicit tumor-specific CTL responses and to significantly delay the growth of B16F10 melanoma tumors implanted at the time of immunization. 21 Flagellin is the main component of the bacterial flagella and induces DC maturation and chemokine secretion by activating NF-kB through their interaction with TLR5. 22, 23 Recombinant flagellin from Salmonella typhimurium induces maturation of human DCs and causes secretion of chemokines. 23 Salmonella flagellin may act as a carrier of epitopes for vaccination against bacteria or viruses 24 and has been shown to enhance immunogenicity of plasmid vaccination. 25 Immunostimulatory properties of the hemagglutininneuraminidase (HN) of the Newcastle disease virus (NDV) have been demonstrated in vitro. 26, 27 Mouse fibroblasts transfected with HN or infected with NDV have been shown to stimulate specific T-cell proliferation with greater efficacy than untreated fibroblasts. 26 A major effect of NDV infection is the induction of IFN-a/b secretion, which can be mediated either through TLRs or by RIG-I-dependent signaling. 28, 29 NDV-infected autologous tumor cells as vaccines have lead to improvement of patient survival for different cancer types. 30 It is still unclear whether NDV HN has a direct effect on immunostimulatory DCs.
In this study, we first used Ad vectors to deliver PAMPencoding genes to tumor cells. The genes encoding P40 from K. pneumoniae or the flagellin from Listeria monocytogenes were cloned in replication-deficient Ad vectors. Their immunostimulatory properties were first investigated in vitro, using co-culture models studying the effects of Ad-transduced tumor cells on the maturation of human monocyte-derived DCs (moDCs) and on the allogeneic proliferation of lymphocytes. In parallel to Ad-PAMPs, we tested the effect of an Ad vector encoding the HN of NDV. Ad-PAMPs and Ad-HN were evaluated in vivo in tumor models as stand-alone treatments, by injecting them intratumorally. The properties of AdPAMPs were further studied in a tumor vaccine setting, by administering them subcutaneously as adjuvants to an Ad vector encoding a tumor-associated antigen.
Materials and methods

Adenoviral vectors
All recombinant viral genomes were derived from an Ad serotype 5 constructed by homologous recombination in Escherichia coli as described earlier. 31 Ad serotype 5 were deleted in E1 (nucleotides 459-3327) and E3 regions (nucleotides 28 592-30 470). Expression cassettes were inserted in place of the E1 region, in sense orientation. For the generation of viruses, the viral genomes were released from the respective recombinant plasmids by PacI digestion and transfected into 293 cells. Virus stock amplification, purification and titration of infectious units (i.u.) were carried out as described earlier. 32 The particle/ i.u. ratio was approximately 30 for all vector preparations. Purified virus was stored in viral storage buffer containing 1 M sucrose, 10 mM Tris-HCl (pH 8.5), 1 mM MgCl 2 , 150 mM NaCl and 0.005% Tween 80.
All transgenes were under the control of the CMV promoter and flanked by a chimeric bglobin-IgG intron and a SV40 polyadenylation signal. The coding sequence of L. monocytogenes flagellin was cloned by PCR from Listeria DNA (kindly provided by Professor F Brombacher, University of Cape Town, Cape Town, South Africa). The gene encoding the P40 from K. pneumoniae was provided by the Centre d'Immunologie Pierre Fabre (CIPF, Saint Julien en Genevois, France). [18] [19] [20] [21] The human CD40L cDNA was purchased from InvivoGen (Cayla, Toulouse, France). The gene encoding the HN of the NDV was derived from plasmid p36/7-HN. 26 The cDNA of the MUC1 tumor antigen was derived from plasmid pHMG-ETAtm (MUC-1) for cloning into Ad vector. 33 Ad vectors were diluted just before use in the viral storage buffer described above.
Tumor cell lines A549 human lung carcinoma cells (American Type Culture Collection (ATCC; CCL 185), LGC Standards, Molshein, France) were cultured in Dulbecco's modified Eagle's medium supplemented with 1 mM sodium pyruvate (Sigma, St Quentin Fallavier, France), 40 mg ml À1 gentamycine (Schering-Plough, Levallois Perret, France), non-essential amino acids (Gibco, Invitrogen, CergyPontoise, France) and 2 mM L-glutamine (Sigma), referred to as 'complete medium', with 10% fetal calf serum (FCS; JRH Biosciences, Sigma).
The CT26 murine colon carcinoma cell line was obtained from ATCC (CRL 2638). The TC1 murine lung tumor cell line was obtained from Dr TC Wu (John Hopkins University, Baltimore, MD). The B16F0-CAR cell line was derived from the B16F0 murine melanoma cell line (ATCC; CRL 6322) stably transfected with an expression plasmid expressing the human cocksackie and adenovirus receptor (CAR), a high-affinity receptor for adenovirus. 34 Cytofluorometric analysis was used to demonstrate CAR expression on the surface of B16F0-CAR cells by staining with the RmcB monoclonal antibody. 35 The expression of CAR by B16F0-CAR cells increased their susceptibility to adenovirus infection approximately 100-fold (unpublished data). Expression of transgene-encoded product on the surface of Ad-transduced A549 cells or tumor cell lines was verified by immunostaining using a biotinylated anti-L. monocytogenes antiserum (Accurate, Westbury, NY) for flagellin detection or a biotinylated anti-Klebsiella antiserum (Accurate) for detection of the P40, both followed by phycoerythrine-conjugated streptavidin (BD Pharmingen, Le Pont de Claix, France). Staining with an anti-NDV-HN monoclonal antibody provided by V Schirrmacher (DKFZ, Heidelberg, Germany), an antihuman CD40L mAb (BD Pharmingen) or an antiMUC1mAb (H23) 33 was detected by an fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin antibody (BD Pharmingen) and analyzed on a FACScan flow cytometer using the CellQuest Pro software (Becton Dickinson, Le Pont de Claix, France).
Co-cultures of human moDCs and Ad-transduced A549 cells Human DCs were derived from elutriated monocytes collected at the Etablissement Franc¸ais du Sang-Alsace (EFS, Strasbourg, France) from healthy blood donors. Cells were cultured in RPMI 1640 medium supplemented with 1 mM sodium pyruvate (Sigma), 40 mg ml À1 gentamycine (Schering-Plough), non-essential amino acids (Gibco), 2 mM L-glutamine (Sigma), 10% FCS and containing 20 ng ml À1 human recombinant granulocyte macrophage-CSF and 10 ng ml À1 IL-4 (PeproTech, Levallois-Perret, France) at 37 1C and 5% CO 2 . The phenotype of immature moDCs obtained on days 5 or 6 of culture was verified by flow cytometry analysis of cell surface markers (CD1a þ , CD14À, HLA-DR þ , CD40 þ , CD80 þ , CD83À and CD86 þ ).
For the co-culture experiments, A549 cells were transduced with Ad vectors at an MOI of 5 and plated in six-well tissue culture plates in complete medium containing 5% FCS at a cell density of 4 Â 10 5 cells per well. In the next day, medium was removed and replaced by 1 ml complete culture medium containing 2% FCS. After 40 h, 5-7 Â 10 5 immature human moDCs at day 5 of differentiation adjusted to 1 ml of their culture medium were added on the infected A549 cells. Co-cultures were incubated for 24 h at 37 1C and 5% CO 2 . Cells were resuspended by gentle scraping and pelleted. Clarified supernatants were collected and frozen until used for cytokine analysis using ELISA. The ELISA kits for human IL-12 (p75), human TNF-a and human IL-10 (R&D Systems, Lille, France) were used for cytokine titrations in culture supernatants as indicated by the manufacturer.
Harvested cells were stained with fluorescein isothiocyanate-conjugated anti-CD86, anti-CD83 or control IgG1 (references BD Pharmingen 555657, ImmunoTech 2410 and BD Pharmingen 555748, respectively) and analyzed by FACS.
Mixed lymphocyte reactions A549 cells were transduced by Ad vectors at an MOI of 20 and plated in duplicates at 2 Â 10 5 cells per well in 24-well plates in 1 ml of complete Dulbecco's modified Eagle's medium containing 5% FCS. In the next day, medium was changed to complete Dulbecco's modified Eagle's medium containing 5% human serum (1 ml per well) and cultures were incubated for 48 h. DCs were differentiated from monocytes as described above. Peripheral blood leukocytes (PBLs) enriched in lymphocytes were obtained by elutriation of cytapheresis from healthy donors at the EFS). DCs and allogeneic PBLs at ratios 1:5 or 1:10 (10 5 moDCs per well and 5 Â 10 5 or 10 6 PBLs per well) in 1 ml of complete RPMI medium containing 5% human serum were added onto A549 cell monolayers. Co-cultures were incubated for 24 h at 37 1C and 5% CO 2 . Cells from each well were resuspended by gentle pipeting to harvest PBLs and DCs but to avoid collecting the A549 adherent monolayer. The cell suspension was centrifuged. Clarified supernatants were collected and frozen before cytokine analysis by ELISA. The cell pellet was resuspended in 2 ml RPMI containing 10% human serum. Cell suspension (200 ml) was seeded in triplicate in round-bottomed 96-well plates. Cultures were incubated for 4 days at 37 1C and 5% CO 2 before the addition of 3H thymidine (1 mCi per well). After 18 h, cells were harvested and thymidine incorporation was measured in a b-counter (TOPCOUNT NTX; Packard, Gmi, Ramsey, Minnesota).
Mouse tumor models C57Bl/6N, B6D2F1 and BALB/c female mice were supplied by Charles River (Les Oncins, France) and were acclimatized in a specific pathogen-free animal facility for 1 week before experiments were started. They were approximately 7 weeks old at the time of the experiments. Specific pathogen-free status was checked by regular serological and bacterial control on sentinel animals. This study was conducted in compliance with CEE directive 86/609 of 24 November 1986 relating to the protection of animals used for experimental or other scientific purposes, and also in compliance with the French law, de´cret no. 87 Tumor volumes and survival were monitored twice a week. For ethical reasons, mice were killed when the tumor mass reached 10% of body weight of the animal at time of inoculation.
Results
Surface expression of PAMPs mediated by transduction of tumor cells with Ad vectors
Genes encoding the flagellin from L. monocytogenes, P40 from K. pneumoniae or HN of NDV were cloned in nonreplicative Ad vectors in CMV promoter-driven expression cassettes. We first verified that transgenes were correctly expressed following transduction of tumor cells with the recombinant Ad vectors in vitro. To this aim, A549 human lung carcinoma cells were transduced and cultured for 48 h before analysis by immunochemistry and flow cytometry. Cell surface immunostaining with antibodies specific to the transgene products were compared with that of A549 cells transduced with an empty Ad vector (Figures 1a-c) . Flagellin, P40 or NDV HN was detected on the surface of A549 cells transduced with the corresponding Ad vector. MOIs varying from 5 to 50 were tested. Figure 1 shows the results obtained at MOIs giving for each transgene the maximal signal intensity. Flagellin expression was best detected by flow cytometry on the surface of A549 cells transduced at an MOI 50 (Figure 1a ), but its expression could also be detected by western blot at MOIs 1, 5, 10 and 50 (result not shown). The level of cell surface expression may vary depending on the transgene. However, bacterial PAMPs such as flagellin or the P40, as well as the viral HN, are efficiently expressed through Ad vectors and found on the surface of transduced tumor cells.
Effects of Ad-PAMPs on the maturation of DCs co-cultured with transduced A549 cells We investigated whether PAMPs expressed by Adtransduced tumor cells could induce the maturation of neighboring DCs. Human moDCs are known to express a wide range of TLRs, including the P40-binding TLR2 and the flagellin-binding TLR5. 36 We set up an in vitro model in which human moDCs were cultured in the presence of A549 cells transduced at an MOI of 5 with Ad-flagellin, Ad-P40 or Ad-HN. Ad-CD40L was used as a positive control, as CD40L is a powerful inducer of DC Adenovirus-PAMPs for cancer immunotherapy C Tosch et al maturation through its interaction with the CD40 molecule on the DC surface. 37 The human CD40L was expressed on the surface of A549 cells transduced with Ad-CD40L (Figure 1d) .
The effect of Ad-transduced A549 cells was studied using moDCs derived from three different blood donors. Upregulation of the CD86 co-stimulatory molecule, measured by flow cytometry, was used to evaluate DC maturation after 24 h of co-culture. For each Ad vector tested, the induction of CD86 on DCs was expressed as a percentage of the CD86 mean fluorescence intensity (MFI) increase obtained with Ad-CD40L when compared with an empty Ad vector. The following formula was used: % CD86 induction ¼ (MFI Ad test ÀMFI Ad-empty )/ (MFI Ad-CD40L ÀMFI Ad-empty ) Â 100.
The data in Figure 2a show that for all three donors, co-culture of moDCs with A549 cells transduced with AdPAMPs upregulated CD86 expression. Upregulation of the maturation marker CD83 was also observed, but varied less in terms of MFI increase (not shown). The increase in CD86 and CD83 expression induced with Ad-CD40L was reproducibly stronger than that observed with Ad-PAMPs. Ad-flagellin was a stronger inducer of DC maturation than Ad-P40 in moDCs from the three donors (mean values of CD86 increase: 49±10% for Adflagellin versus 25 ± 11% for Ad-P40). Ad-HN produced only a marginal effect on moDCs with a reproducible 15±1% induction of CD86.
Cytokine secretion by moDCs in culture with Ad-PAMP-transduced A549 cells TNF-a was titrated in culture supernatants of human moDCs with Ad-transduced A549 cells (Figure 2b ). For three different donors, Ad-flagellin induced only a minor increase in TNF-a secretion (mean 76±19 versus 49±9 pg ml À1 with Ad-empty) when compared with that induced by Ad-CD40L (above 1000 pg ml
À1
). Neither Ad-P40 nor Ad-HN induced a detectable increase of TNF-a secretion.
The P40 has been reported to increase IL-12 p75 secretion by human and murine macrophages. 20 We therefore investigated the presence of IL-12 in co-culture supernatants of human or murine DCs with Ad-transduced A549 cells. Low levels of IL-12 were found in co-cultures with Ad-PAMPs, Ad-HN or Ad-empty. In contrast, IL-12 p75 secretion observed in the presence of Ad-CD40L was increased by more than 100-fold (data not shown).
In co-culture experiments, moDCs secreted high amounts of IL-10 in the presence of Ad-CD40L (data not shown). In contrast, basal levels of IL-10 produced by DCs were not significantly increased in the presence of Ad-PAMP-transduced A549 cells. Transduced A549 cells alone did not secrete any IL-10 or IL-12.
Altogether, these results show that in this system, expression of the flagellin, P40 or the NDV HN on A549 cells does not affect the secretion of the cytokines examined. In contrast, CD40L expression by Ad-transduced tumor cells induces strong secretion of TNF-a, IL-10 and IL-12 by moDCs.
Stimulation of T-cell proliferation and cytokine secretion in allogeneic MLR by Ad-PAMP transduction of A549 cells
As shown above, co-stimulatory molecule expression by human moDCs was augmented following culture in the presence of tumor cells transduced with Ad-PAMP when compared to cells transduced with Ad-empty. To see whether this correlated with an increased immunostimulatory function of DCs, we performed mixed lymphocyte reaction (MLR) experiments in which human moDCs and PBLs were co-cultivated in the presence of A549 cells transduced with Ad-PAMPs at an MOI of 20. Culture supernatants were sampled for the determination of IFN-g, and cell proliferation was measured by the incorporation of [ 
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C Tosch et al presence of A549 cells transduced with Ad-CD40L (Figure 3a) . In co-cultures of A549 cells transduced with Ad-flagellin or Ad-P40, lymphocyte proliferation was increased when compared with MLRs performed in the presence of Ad-empty-transduced A549 cells. This was observed whether or not moDCs were added to the PBLs, which also contained non-lymphocytic cells from peripheral blood. In conditions using 10 6 responder PBLs, in the absence of additional moDCs, cell proliferation was increased 3-fold with Ad-P40, 5-fold with Ad-flagellin and 10-fold with Ad-CD40L when compared with the proliferation observed with Ad-empty.
IFN-g secretion in MLR was correlated with cell proliferation. It was markedly induced in co-cultures of PBLs with A549/Ad-PAMPs (Figure 3b) , as well as on addition of allogeneic moDCs (data not shown). IFN-g was not detected in MLR with non-transduced A549 cells (not shown), and hardly detected with Ad-empty-transduced A549 cells (Figure 3b) . IFN-g secretion was lower with Ad-PAMPs than with Ad-CD40L; Ad-flagellin transduction of A549 cells resulted in higher IFN-g secretion by co-cultured PBLs when compared with Ad-P40.
Intratumoral injection of Ad-PAMPs alone in immunocompetent mouse models provides weak therapeutic effects Immunocompetent mouse tumor models were used to evaluate the effect of Ad-PAMPs injected directly into established tumors. It was expected that the innate immune response might be stimulated locally by the expression of PAMPs within the tumor, favoring the development of a specific immune response and tumor regression.
The following syngeneic subcutaneous tumor models were used: B16F0-CAR (melanoma), RenCa (renal carcinoma), CT26 (colon carcinoma) or TC1 (lung carcinoma). Three injections were performed into palpable tumors at 2-3 day intervals with Ad-PAMPs, Ad-HN (which, as shown above, did not efficiently stimulate DC maturation in vitro) or Ad-empty.
In most of these models (RenCa, TC1 and CT26), treatment with Ad-PAMPs did not provide significant effect on tumor growth or mouse survival (results not shown). However, significant results were obtained in the B16F0-CAR melanoma tumor model. B16F0-CAR is a tumor cell line derived from B16F0 melanoma cells stably transfected with the CAR. 34 Expression of CAR increases the efficacy of transduction by Ad vectors, which otherwise infect murine cells with low efficacy as compared with human cells (PE, unpublished results). In mice bearing B16F0-CAR tumors, treatment with Ad-P40 transiently inhibited tumor growth between days 30-40 (days 20-30 after Ad injection) (Figure 4a ). Survival was also transiently but significantly increased (log-rank test P ¼ 0.018) in the mouse group that received this vector when compared with the group injected with Ad-empty (Figure 4b) . At day 49, whereas 13, 17 and 20% of mice survived in the groups injected with Ad-flagellin, Ad-HN or Ad-empty, respectively, 47% of mice treated with Ad-P40 were still alive.
Combination of Ad-PAMPs with Ad-MUC1 improves therapeutic vaccination against RenCa-MUC1 tumors
The immunoadjuvant effects of Ad-PAMPs were also tested in a model of therapeutic vaccination against RenCa-MUC1 tumors. B6D2 mice were inoculated with RenCa renal carcinoma cells stably transfected to express the tumor-associated antigen MUC1 (RenCa-MUC1). 33 Ad-MUC1 was combined with Ad-PAMPs, Ad-HN or Ad-empty for subcutaneous administration to tumorbearing mice. At days 20-30 after tumor inoculation, (Figure 5a ). These results are consistent with survival rates at day 110 after tumor implantation, with 20 and 28% survival for groups co-treated with Ad-P40 and Ad-flagellin, respectively, versus 7 and 0% in mice co-treated with Ad-empty or Ad-HN (Figure 5b) . The difference between the Ad-flagellin or Ad-P40 þ Ad-MUC1-treated mice and those treated with Ad-empty or Ad-HN þ Ad-MUC1 is statistically significant (log-rank test P ¼ 0.039).
Discussion
In this study, we first used in vitro models to find out whether PAMPs, when expressed by transduced tumor cells, induce the phenotypic and functional maturation of human moDCs. DC maturation was indeed stimulated by tumor cell transduction with Ad-flagellin and Ad-P40, but not as efficiently as with Ad-CD40L. These results correlate with the stimulation of lymphocyte proliferation and IFN-g secretion in MLR experiments performed in the presence of Ad-PAMP-or Ad-CD40L-transduced A549 cells. Ad-flagellin and Ad-P40 were then tested in syngeneic mouse tumor models, first by direct injection into established tumors. Ad-P40 produced a weak therapeutic effect on tumor sizes and survival in B16F0-CAR tumor-bearing mice, whereas Ad-flagellin did not produce any effect in this model. No effect was observed in three other syngeneic tumor models (RenCa, TC1 and CT26) for any of the viruses tested. However, in a therapeutic vaccination protocol, where Ad-PAMPs were used as adjuvants in combination with an Ad-MUC1 tumor antigen vaccine administered subcutaneously to 
Adenovirus-PAMPs for cancer immunotherapy C Tosch et al
RenCa-MUC1 tumor-bearing mice, Ad-P40 and Adflagellin reduced tumor sizes and improved survival. DCs cultivated for 24 h with Ad-flagellin-or Ad-P40-transduced A549 cells may be described as 'semi-mature': expression of the co-stimulatory molecule CD86 was upregulated, but not as much as following culture with Ad-CD40L. Using an Ad vector encoding the HN of NDV, which has not been characterized as a PAMP, transduction of A549 cells did not result in significant modulation of the DC maturation state. In correlation with this lack of DC stimulatory capacity in vitro, Ad-HN did not show any therapeutic effects in the tumor models tested. This favors the idea that a viral infection leading to interferon induction is key for the effect seen with NDV.
In the DC/tumor cell co-culture model, secretion of the pro-inflammatory cytokine TNF-a by moDCs was dramatically enhanced by Ad-CD40L, whereas it was only weakly induced by Ad-flagellin. No effect was observed with Ad-HN or Ad-P40. The latter result was unexpected because the P40 has been reported to stimulate TNF-a secretion by human moDCs or monocytes. 18, 23, 25 Secretion of IL-12 was not induced by transduction with Ad-PAMPs, whereas Ad-CD40L potently upregulated this important Th1-inducing cytokine. It has already been shown that flagellin treatment of human DCs does not stimulate IL-12 secretion. 23 In the case of P40, macrophages treated with the purified protein have been reported to secrete IL-12, but only in low amounts. 20 A recent study indicates that only the IL-12 p40 subunit can be secreted by TLR-stimulated DCs, whereas IFN-g or DC stimulation by activated T cells is required for the production of IL-12 p75. 38 Ad-PAMPs did not cause the secretion of the 'immunosuppressive' cytokine IL-10 by DCs. In contrast, Ad-CD40L induced high levels of this cytokine, which is believed not to be beneficial for cancer immunotherapy as notably shown in a recent study. 39 The induction of DC maturation by A549 cells transduced with Ad-flagellin or Ad-P40 was correlated by an increased stimulation of lymphocyte proliferation in MLR. In this assay, Ad-flagellin appeared to have the strongest effect on lymphocyte proliferation, maybe due to the fact that T cells express TLR5 and are directly stimulated by flagellin. 40 IFN-g expression is crucial for immune response to cancer. 13 The secretion of IFN-g was induced by Ad-PAMPs, with a superior effect of Ad-flagellin as compared with Ad-P40.
In mouse models where Ad-PAMPs were administered intratumorally, only marginal or no effects were observed in the increase in tumor volumes or in survival. However, Ad-P40 showed some efficacy in the B16F0-CAR model for both of these criteria. The higher susceptibility to transduction by Ad conferred by the expression CAR on B16F0 melanoma cells may contribute to this effect of Ad-P40. However, the therapeutic effect of Ad-P40 on tumor growth was only transient, which may be due to the negative selection of P40-expressing tumor cells, potentially more immunogenic than their non-transduced counterparts. It should be tested whether a prolonged treatment with Ad-P40, with continuing repeated injections, improves its therapeutic benefits.
When expression of the P40 protein following Ad transduction was investigated in the murine tumor cell lines, the level of expression was found to vary between cell lines (data not shown). Expression of the P40 could not be detected in the CT26 cell line in vitro, which may explain the lack of effect of Ad-P40 in the CT26 tumor model. Low or no expression may result from inefficient cell transduction by Ad vectors. The CT26 cell line is sensitive to NDV virus infection 41 but is poorly sensitive to Ad infection, as tested using an Ad-GFP (green fluorescence protein) vector. Infectivity studies were performed on TC1, RenCa, CT26 and B16F0-CAR cells transduced with varying MOIs of Ad-GFP. TC1 and B16F0-CAR cells were transduced with high efficiency, both giving 52±4% GFP-positive cells 24 h after transduction at an MOI of 1 and 96 and 80 ± 4%, respectively, at an MOI of 10. RenCa cells were slightly more resistant to infection, with only 11±1% GFPpositive cells at an MOI of 1, but 76 ± 1% at an MOI of 10. In contrast, CT26 cells revealed very resistant to transduction by Ad-GFP, giving only 1% positive cells at an MOI of 1 and 19±3% at an MOI of 100 (unpublished results). This raises the possibility that some transgenes cannot be expressed through Ad vectors in certain types of tumor cells, which may represent an obstacle to Adbased therapy of cancers using intratumoral administration.
For Ad-flagellin, no beneficial effect on tumor progression was observed in any of the models tested using intratumoral administration. Recently published data 42 show that purified flagellin administered peritumorally 8-10 days after tumor implantation did not affect the growth rate of a poorly immunogenic tumor, whereas it significantly inhibited the growth of an antigenic human ErB-2-transfected tumor variant. Low immunogenicity of B16F0-CAR cells might explain the lack of effect observed for Ad-flagellin.
Cancer-induced immunosuppression has been characterized notably by the presence of tumor-derived immunosuppressive cytokines, such as IL-10 or TGFb which, among other effects, can inhibit DC maturation and functions. 1, 4, 5, 13 Thus, in the C26 model, it has been shown that intratumoral administration of CpG induces tumor regression only when combined with anti-IL-10R mAb treatment. 9 Our in vitro results showed that DCs cultured in the presence of Ad-PAMP-transduced tumor cells did not secrete IL-12, whereas they did when stimulated with Ad-CD40L. Basal levels of IL-10 present in our co-culture system may contribute to inhibit IL-12 production on TLR stimulation. Similarly, in the tumor models studied, IL-10 and other cytokines may contribute to maintain unresponsiveness to TLR signals delivered intratumorally.
In the RenCa-MUC1 model of therapeutic vaccination, Ad-PAMPs combined with Ad-MUC1 and administered subcutaneously improved mouse survival and inhibited early tumor growth. Purified P40 has previously been found to stimulate the immune response against a TRP-2 peptide antigen present on B16F10 tumors and to confer protection against these tumors when administered with the peptide at the time of tumor implantation. 21 In our RenCa-MUC1 model, Ad-flagellin combined with Ad-MUC1 produced the highest survival rates when compared with Ad-P40 or Ad NDV HN. Ad-flagellin also showed the strongest effects in vitro on the maturation of human moDCs and on lymphocyte proliferation in MLR. This PAMP has recently been reported to function as an adjuvant when expressed by a plasmid. 25 Our results suggest that it may also be an interesting adjuvant for a tumor-associated antigen vaccine when expressed from an Ad vector. Further studies are needed to dissect the properties of Ad-PAMPs as vaccination adjuvants. Our results show that Ad-PAMPs have immunostimulatory properties and could be effective adjuvants for cancer immunotherapy using tumor antigen vaccines.
